Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for misleading statements regarding its Phase 3 clinical programs, potentially affecting investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc and certain officers for alleged violations of federal securities laws during the Class Period from June 5, 2023, to December 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Mereo securities during the specified Class Period [2]. - The Complaint alleges that Mereo provided positive statements to investors while concealing material adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by April 6, 2026, although sharing in any recovery does not require serving as lead plaintiff [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - The complaint against Mereo BioPharma alleges violations of federal securities laws due to false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints in reducing annualized clinical fracture rates compared to control groups [2] Group 1: Legal Proceedings - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought and is representative of the class members [3] - Any member of the putative class can move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [3] Group 2: Whistleblower Information - The law firm encourages individuals with information regarding Mereo BioPharma's conduct, including whistleblowers and former employees, to come forward [4]

LOS ANGELES--(BUSINESS WIRE)--Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MREO. ...

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging that the company misled investors regarding the results of its Phase 3 studies for setrusumab, which did not meet primary endpoints, leading to significant stock price decline [1] Group 1: Allegations and Misleading Information - The lawsuit claims that Mereo BioPharma provided investors with overly optimistic statements about the Phase 3 ORBIT and COSMIC studies for setrusumab, suggesting confidence in its efficacy in reducing annualized fracture rates [1] - It is alleged that while making positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 programs, which ultimately did not achieve their primary endpoints [1] Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoints, Mereo's American Depository Shares (ADS) plummeted from $2.31 to $0.29, representing a decline of over 87.7% [1]

Core Viewpoint - Mereo BioPharma Group plc is facing a securities fraud lawsuit, and investors have the opportunity to lead the case with the Schall Law Firm [1] Group 1 - The lawsuit presents a chance for Mereo investors to take a proactive role in addressing the alleged securities fraud [1]

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for allegedly providing misleading information regarding the results of its Phase 3 studies for setrusumab, leading to significant investor losses [2][7]. Allegation Details - The lawsuit claims that Mereo's management made positive statements about the Phase 3 ORBIT and COSMIC studies, asserting confidence in setrusumab's ability to reduce annualized fracture rates, while concealing adverse facts about the studies' true outcomes [7]. - The complaint highlights that neither the ORBIT nor the COSMIC studies met their primary endpoints, which resulted in investors purchasing Mereo's American Depositary Shares (ADS) at inflated prices [7]. Impact on Share Price - Following the announcement on December 29, 2025, that the studies did not meet their primary endpoints, Mereo's ADS price plummeted from $2.31 per share to $0.29 per share, marking a decline of over 87.7% [7].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 5, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no late ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Fa ...

Core Viewpoint - A securities class action lawsuit has been filed against Mereo BioPharma Group plc for allegedly providing misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Mereo securities between June 5, 2023, and December 26, 2025 [1]. - The Complaint claims that Mereo's misleading statements led to shareholders purchasing its American Depositary Shares (ADS) at artificially inflated prices [2]. Group 2: Study Results - The Complaint alleges that the Phase 3 ORBIT and COSMIC studies failed to achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonate control groups [2][3]. - Despite improvements in bone mineral density, neither study met its primary endpoint [3]. Group 3: Market Reaction - Following the announcement on December 29, 2025, that the studies did not meet their primary endpoints, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7% [4].